A declassified CIA document from 1951 reveals that a Soviet scientist named Professor V.V. Alpatov published research in 1950 identifying deep biochemical similarities between internal parasites and malignant tumours, complete with existing compounds already shown effective against both. That translated report was stamped Confidential and kept from Western scientific discourse for sixty-one years, and now the largest real-world human study of anti-parasitic drugs in cancer patients has reported an 84.4% clinical benefit ratio at six months, a result so biologically coherent it makes the original suppression impossible to explain as mere institutional oversight.
The Cancer Cure They Classified: A 70-Year Cover-Up Coming Into the Light
Picture a scientist in Leningrad in October 1950, publishing a paper in a Russian scientific journal that proposes something both elegant and explosive: that internal parasites and malignant tumours share biochemical characteristics profound enough to suggest that the same agents capable of killing parasites might also disrupt cancer growth. The paper, authored by Professor V.V. Alpatov and published in Priroda, was doing what science is supposed to do: putting an idea into the open where it could be tested, challenged, and built upon.
Instead, it was translated by the Central Intelligence Agency, stamped Confidential, distributed to the State Department, the Navy, the Army, the Air Force, the NSR Board, and the FBI, and then effectively removed from Western scientific discourse for sixty-one years. The document was not approved for public release until September 2011.
An entire generation of oncological research developed without access to a hypothesis that, had it been available and pursued, might have redirected the field toward something far simpler and far less profitable than what eventually emerged.
What Professor Alpatov Actually Found
The CIA document is precise about the specific biological similarities Alpatov identified between endoparasites and malignant tumour tissue. Three characteristics stand out:
- The presence of specific antigens in both malignant tissue and parasites, a shared immunological signature that distinguishes both from healthy cells
- Optical inversion of receptors to certain active compounds, meaning both cancer tissue and parasitic organisms respond to the same molecular signals in ways that differ fundamentally from healthy tissue
- Peculiarities in purine metabolism connected to the synthesis of nucleic acids, a shared disruption at the level of the cell’s own replication machinery
Alpatov’s conclusion was not fringe speculation. He pointed to existing research from 1938 in which a compound called Myracyl D was found effective against both Bilharzia (a parasitic disease) and malignant tumours. He cited a guanine analogue called Guanozolo which suppressed nucleic acid synthesis in both infusoria and cancer tumours in mice. The biochemical overlap, in other words, was not theoretical. It had already produced compounds with dual anti-parasitic and anti-cancer activity before 1950.
Alpatov’s paper closed by noting that malignancy appeared closely connected with alterations in the chemical properties of protoplasm, the specific properties of enzymes, and the peculiarities of protein carriers. Work on tumour proteins in the USSR, he wrote, was assuming particular importance. That work was quietly translated, classified, and set aside.
The 2026 Study That the Suppression Now Explains
What makes the classified document so significant in 2026 is not that it stands alone. It is that it now stands alongside the largest real-world human analysis of anti-parasitic drugs in cancer patients ever conducted.
Published in April 2026 by a team including Nicolas Hulscher MPH, Peter McCullough MD MPH, and Harvey Risch MD PhD, the study evaluated 197 cancer patients prescribed a compounded ivermectin and mebendazole protocol off-label through licensed US healthcare providers, with results representing one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.
At the six-month follow-up, the Clinical Benefit Ratio was 84.4%. Of those completing follow-up, 48.4% reported the strongest positive outcomes: 32.8% showed no current evidence of disease and 15.6% reported tumour regression. A further 36% reported disease stabilisation.
These are not marginal results. There are now hundreds of preclinical studies in both cell systems and animal models showing that anti-parasitic agents like ivermectin and mebendazole exert broad, multi-target anti-cancer effects across more than a dozen tumour types. The clinical signal observed is biologically coherent.
Alpatov identified the biochemical logic in 1950. The clinical results are confirming it in 2026. Between those two data points sits sixty-one years of classified silence.
Why Cheap Drugs Cannot Get a Fair Hearing
The mechanism of suppression here does not require bad actors in darkened rooms. It requires only the structural realities of pharmaceutical development. Neither ivermectin nor mebendazole can be profitably patented. Without patent protection, there is no commercial incentive to fund the large-scale randomised trials that regulatory agencies require before a treatment can be officially approved and widely adopted.
This is not a conspiracy. It is a feature of the system that is openly acknowledged by researchers, regulators, and pharmaceutical economists alike. The consequence is that drugs showing significant clinical signals but lacking patentable novelty are systematically under-investigated, regardless of the evidence accumulating around them.
When the CIA’s translated summary of Alpatov’s 1950 paper was classified and distributed across the US intelligence and defence apparatus without entering Western scientific journals, it ensured that a biologically grounded hypothesis did not reach the oncologists who were, at that very moment, laying the foundations of modern cancer treatment. The patent-driven pharmaceutical model that developed in the subsequent decades was built on a research landscape from which this line of inquiry had been quietly removed.
The Moment of Reckoning
The formerly classified document now sits in the CIA’s own public reading room, declassified and downloadable. The 2026 Hulscher study is available as a preprint on the Zenodo research repository, undergoing peer review. The biochemistry Alpatov described in 1950 is consistent with the multi-target mechanisms now confirmed in preclinical literature. The clinical signal in real-world patients is, as the researchers themselves state, not surprising. It is biologically coherent.
What is not yet coherent is the continued absence of large, funded, independent clinical trials. That absence is the clearest signal of all about where the priorities of the system actually lie, and why the work of staying informed, asking hard questions, and holding your own sovereignty over health decisions has never been more important.
Original Article: Europe Reloaded
Join the Conversation
If a classified intelligence document confirms that the biochemical basis for using anti-parasitic drugs against cancer was known and suppressed in 1950, and a 2026 real-world study of 197 patients is now reporting an 84% clinical benefit rate, what does that tell you about who the cancer industry has truly been serving? And what steps, if any, are you taking to reclaim your own authority over health decisions in a system that may not have your best interests at its centre? Share your experiences and insights below.
